Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Edesa Biotech (EDSA) Cost of Revenue (2016 - 2020)

Edesa Biotech's Cost of Revenue history spans 8 years, with the latest figure at $2314.0 for Q3 2020.

  • For Q3 2020, Cost of Revenue changed N/A year-over-year to $2314.0; the TTM value through Jun 2021 reached $2314.0, down 84.86%, while the annual FY2020 figure was $17601.0, N/A changed from the prior year.
  • Cost of Revenue for Q3 2020 was $2314.0 at Edesa Biotech, up from $1472.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $595341.0 in Q3 2016 and bottomed at $1472.0 in Q2 2020.
  • The 5-year median for Cost of Revenue is $64708.0 (2017), against an average of $88452.1.
  • The largest annual shift saw Cost of Revenue surged 291.05% in 2016 before it crashed 90.45% in 2017.
  • A 5-year view of Cost of Revenue shows it stood at $78565.0 in 2016, then grew by 24.8% to $98050.0 in 2017, then fell by 19.59% to $78838.0 in 2018, then crashed by 95.21% to $3778.0 in 2019, then plummeted by 38.75% to $2314.0 in 2020.
  • Per Business Quant, the three most recent readings for EDSA's Cost of Revenue are $2314.0 (Q3 2020), $1472.0 (Q2 2020), and $10037.0 (Q1 2020).